U.S. Senator Elizabeth Warren has urged the U.S. Federal Trade Commission to review CVS Health Corp's $9.5-billion acquisition of Oak Street Health Inc as well as other merger deals in the sector.

The U.S. Justice Department has dismissed its own appeal challenging UnitedHealth Group's nearly $8 billion acquisition last year of Change Healthcare, a court filing showed.

The $3.8 billion merger between JetBlue Airways Corp and Spirit Airlines Inc is in the crosshairs of the U.S. Justice Department, making it the latest major deal to attract tough regulatory scrutiny. Large deals, including Nvidia Corp's bid to buy UK-based chip firm Arm Ltd, have been abandoned following regulatory hurdles. Here is a list of some mergers that faced strong antitrust scrutiny under the Biden regime: DEALS UNDER SCRUTINY

Insurer Elevance Health Inc has agreed to pay $2.5 billion for its previously announced purchase of Blue Cross and Blue Shield of Louisiana, Bloomberg News reported on Monday, citing documents.

Insurer Elevance Health Inc has agreed to pay $2.5 billion for its previously announced purchase of Blue Cross and Blue Shield of Louisiana, Bloomberg News reported on Monday citing documents.

Humana Inc will exit the employer-based insurance business over the next 18 to 24 months, it said on Thursday, to focus primarily on government-backed programs such as Medicare for people aged 65 and older and its specialty businesses.

Humana Inc said on Thursday it will be exiting the Employer Group insurance business.

The U.S. government will begin imposing penalties in 2025 on drug companies that charge its Medicare program prices that rise faster than inflation, the Centers for Medicare & Medicaid Services said on Thursday.

The U.S. government will begin imposing penalties in 2025 on drug companies that charge its Medicare program prices that rise faster than inflation, the Centers for Medicare & Medicaid Services said on Thursday.

Centene Corp has reached a $215.4 million settlement with California to resolve accusations it overcharged a state program for affordable healthcare by falsely inflating its costs for providing prescription drugs to patients.